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spreading on IC compared to WT. IC adhesion-dependent H2O2
production of neutrophils was also increased in PILR -/- mice
compared to WT animals.
Conclusions: PILR deﬁciency resulted in deteriorated renal damage
in murine antibody-mediated glomerulonephritis compare to WT
mice. The present study indicated that PILR negatively regulates
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Introduction: The immune system controls the gut microbiota.
Transplant recipients are treated with immunosuppressive (IS)
therapies which could impact host-microbial interactions. We
examined the impact of IS drugs on gut microbiota and on the
secretion of ileal antimicrobial peptides.
Methods: Mice were treated for 14 days with prednisolone,
mycophenolate mofetil, tacrolimus, a combination of these 3 drugs,
everolimus or water. Faeces were collected before and after treat-
ment initiation. Ileal samples were collected after sacriﬁce. Faecal
and ileal microbiota was analyzed by pyrosequencing of 16S rRNA
genes, and C-type lectins were assessed in ileal tissues by RT-qPCR.
Results: Prednisolone decreased Bacteroidetes and increased Fir-
micutes in the faeces. While prednisolone disrupted faecal micro-
bial community structure, no single OTU was consistently affected
in experimental replicates. In ileal samples, the genus Clostridia
sensu stricto was dramatically reduced in the prednisolone and
combined IS drug groups. These modiﬁcations corresponded to an
altered expression of C-type lectins, Reg3 and Reg3. Interestingly,
the combined IS treatment enabled a commensal Escherichia coli to
ﬂourish, and dramatically increased colonization by uropathogenic
E. coli strain 536.
Conclusions: IS treatment alters innate antimicrobial defenses and
disrupts the gut microbiota which leads to overgrowth of indige-
nous E. coli and facilitates colonization by opportunistic pathogens.
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Introduction: Induction therapy of proliferative lupus nephritis
still requires the use of unselective immunosuppressive drugs with
signiﬁcant toxicities. More speciﬁc drugs with equal efﬁcacy but
fewer side effects are needed. In search of suitable molecular targets
we considered monocyte chemoattractant protein (MCP-1/CCL2)
and stromal cell-derived factor (SDF-1/CXCL12), which both
contribute to the onset and progression of proliferative lupus
nephritis yet through different mechanisms. We hypothesized that
dual antagonism of the homeostatic chemokine CXCL12 and the pro-
inﬂammatory chemokine CCL2 could be as potent on lupus
nephritis as the unselective and toxic immunosuppressant cyclo-
phosphamide (CYC).
Methods: We used l-enantiomeric RNA Spiegelmer chemokine
antagonists, i.e. the CCL2-speciﬁc mNOX-E36 and the CXCL12-
speciﬁc NOX-A12. Female MRLlpr/lpr mice were treated (subcu-
taneous injection) from week 12 to 24 of age of age either with
single regimen of anti-CXCL12 (13.4mg/kg) or anti-CCL2 (14.4 mg/
kg) or both along with standard regimen with cyclophosphamide
(CYC) (30mg/kg).
Tissues were harvested for histopathological evaluation at the
end of the treatment period. Blood and urine samples were obtained
at monthly intervals for the estimations of urinary albumin (ELISA:
Bethyl Labs, Montgomery, TX, USA) as well as serum and urinary
creatinine (Jaffé reaction: DiaSys Diagnostic Systems, Holzheim,
Germany). Inﬂammatory gene proﬁle was determined by RTPCR.
All experiments were performed according to German animal pro-
tection laws and had been approved by the local government
authorities.
Results: Dual blockade was signiﬁcantly more effective than
monotherapy in preventing proteinuria and BUN. Dual blockade
was also more effective in controlling the histopathological indices
of disease activity and chronicity. Dual blockade reduced IgG im-
munoglobulins, CD3+ lymphocytes and macrophages more efﬁ-
ciently than monotherapy. Dual blockade also reduced renal IL-6,
IL-12p40, CCL5, CCL-2 and CCR2 mRNA expression. Effects of dual
blockade on kidney functional parameters are at par with CYC
standard regimen.
Conclusions: Dual blockade of CCL2 and CXCL12 can be as potent
as CYC to suppress the progression of proliferative lupus nephritis
in female MRLlpr/lpr mice probably because the respective che-
mokine targets mediate different disease pathomechanisms, i.e.
systemic autoimmunity and peripheral tissue inﬂammation.
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Introduction: Lymphocytes occupy pivotal roles in immune-medi-
ated kidney diseases. However the respective contributions of
different lymphocyte subsets in diseased human kidneys are not
certain, with previous studies limited by the methodology of
immunohistochemistry to identify inﬁltrating cells.Kidney International Reports (2016) 1, S1–S22
